Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pharmacokinetic interactions between simeprevir and ledipasvir with sofosbuvir in treatment-naive chronic hepatitis C genotype 1
2015-000459-25Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of simeprevir, ledipasvir and sofosbuvir in hepatitis C virus infection (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Steady-state simeprevir pharmacokinetic parameters. Started Mar 2015; status: completed.
02
Drugs
simeprevirledipasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2015-000459-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000459-25.